In particular, further studies are required to disclose the precise mechanisms underlying the glomerular and tubulointerstitial actions of mTORC1 and mTORC2 in order to improve management of renal diseases and to reduce glomerular side effects and proteinuria reported with the traditional mTOR inhibitors currently available. This evidence concerns the gene MTOR and kidney disorder.